Clinical Trials Logo
  1. Home
  2. Postmenopausal Symptoms
  3. NCT01361308

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) — N30-003  

Postmenopausal Symptoms Clinical Trial

Official title:
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

Clinical Trial Summary

The purpose of this study is to assess the safety & efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.

Clinical Trial Description

This is 12-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg and placebo capsules in subjects with moderate to severe postmenopausal VMS, defined as follows:

- Moderate VMS: Sensation of heat with sweating, able to continue activity

- Severe VMS: Sensation of heat with sweating, causing cessation of activity

The study is comprised of a screening period, a run-in period, a baseline visit, and a double-blind treatment period. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01361308
Study type Interventional
Source Noven Therapeutics
Contact
Status Completed
Phase Phase 3
Start date May 2011
Completion date February 2012
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06369363 - Estrogen Deficiency on Cardiovascular Risk Early Phase 1
Not yet recruiting NCT01170195 - Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms Phase 1/Phase 2
Completed NCT00535288 - Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) Phase 3
Recruiting NCT06030388 - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women N/A
Not yet recruiting NCT05557799 - Photobiomodulation in Post Menopause Genitourinary Syndrome Phase 1/Phase 2
Recruiting NCT04893226 - Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women N/A
Completed NCT03684096 - Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes N/A
Completed NCT01268046 - Aging and Estrogen on Cortical Function Phase 1/Phase 2
Recruiting NCT05659693 - The Effect of Digital Literacy Education Given to Postmenopausal Women on Health Literacy and Quality of Life N/A
Completed NCT03572153 - A Mind-Body Intervention for Hot Flash Management N/A
Not yet recruiting NCT06197568 - Open-Label Study of Vaginal AZU-101 in Postmenopausal Women Phase 1/Phase 2
Withdrawn NCT03854396 - Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Phase 3
Unknown status NCT00905723 - The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women Phase 3
Recruiting NCT05351476 - Exercise Training and Fat Metabolism in Postmenopausal Women N/A
Completed NCT06096818 - Kegel and Abdominal Exercises on Urinary Incontinence Severity, Quality of Life, and Sleep Quality in Menopausal Women N/A
Completed NCT03150407 - Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness N/A
Recruiting NCT04129060 - Cholinergic Health After Menopause (CHAMP) Early Phase 1
Recruiting NCT04493333 - Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors Phase 2
Completed NCT03786809 - Vascular Effect of CIMICIFUGA RACEMOSA N/A
Not yet recruiting NCT05922800 - Effectiveness of Electro-Press Needle and Gamma-Oryzanol for Menopause-associated Hot Flashes N/A